Navigation Links
Intra-Cellular Therapies Announces Positive Results with ITI-002 in Pre-Clinical Models of Parkinson's Disease
Date:10/1/2010

ge, reaching 4% of the population over 80. Mean age of onset is around 60 years, although in 5-10% of cases the onset is earlier and occurs between the ages of 20 and 50. Primary symptoms include decreased motor function caused by appearance of tremor, rigidity, bradykinesia, and postural instability.  Many patients co-morbidly exhibit impaired cognitive function, depression and excessive day time sleepiness. Dopamine replacement therapies, such as L-DOPA, are the current treatments of choice. However, with time on drug and with disease progression, these drug therapies often lose effectiveness and can cause unwanted side effects such as dyskinesias and hallucinosis.

ABOUT INTRA-CELLULAR THERAPIES

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company developing novel drugs for the treatment of diseases and disorders of the Central Nervous System (CNS).  Building on the science generated from the Nobel Prize winning laboratory of Dr. Paul Greengard at The Rockefeller University, the Company develops compounds that have the potential to treat a wide range of diseases associated with the CNS, including schizophrenia, sleep disorders, Parkinson's disease and Alzheimer's disease, cognitive deficits in schizophrenia, depression and female sexual dysfunction, and other disorders pertaining to Women's Health.  To aid in the development process, ITI incorporates its CNSProfile™, a state-of-the-art platform that allows the Company to choose compounds with the strongest potential to succeed in these difficult to treat diseases.


'/>"/>
SOURCE Intra-Cellular Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
2. Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
3. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
4. Vital Therapies Expands SILVER Trial to Saudi Arabia
5. Prometheus and Tarrot Laboratories Collaborate to Identify Markers Associated With Response to Anti-TNF Therapies in Crohns Disease
6. PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies
7. US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research
8. NeoStem to Receive $700,000 from the U.S. Armys Medical Research and Materiel Command to Advance Adult Stem Cell Therapies in Treating Traumatic Wounds
9. New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
10. ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
11. 5th Annual Summit to Feature New Stem Cell Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... trained personnel, and detection dogs to safeguard airports ... revolutionary new electronic chip with nano-sized chemical sensors ... , The groundbreaking nanotechnology-inspired sensor, devised by Prof. ... of Chemistry and Center for Nanoscience and Nanotechnology, ... up the scent of explosives molecules better than ...
(Date:7/24/2014)... 24, 2014 Research and Markets ... Culture Market 2014-2018" report to their offering.  ... culture is the in vitro growth of plant or ... studies, and biopharmaceutical production. Cell culture is a crucial ... instruments and cell culture consumables are necessary for the ...
(Date:7/24/2014)... July 24, 2014 Three companies from ... in Livestrong’s Big C Competition. Out of 700 competition ... headed to the semi-final round. In this round twenty ... accelerator program, complete with mentoring from thought-leaders and medical ... part of the angelMD commitment to the Livestrong vision ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 The first ... Dose Escalation in First in Human Studies” will cover ... better go/no-go decisions. , With increasing R&D costs and ... companies need to maximize the knowledge collected in early ... and improve success in late stage development. , Next, ...
Breaking Biology Technology:Nano-sized chip 'sniffs out' explosives far better than trained dogs 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 23 angelMD Startups Make Livestrong Big C Semi-finals 2Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2
... PARIS, Sept. 7, 2011 Cellectis (Alternext: ... announced that its nuclease production capacity has ... costs. Industrialization of the nuclease manufacturing gives ... commercial subsidiary of Cellectis, the potential to ...
... and OXFORD, England, Sept. 7, 2011 CMC Biologics ... entered into a non-exclusive license agreement providing OBT with ... financial terms of which have not been disclosed, covers ... by OBT. CMC Biologics, CHEF1 cell line development platform ...
... Inc. (Nasdaq: RDEA ) announced today that it ... and Drug Administration (FDA) and successfully reached agreement on the ... plan: the overall size and design of the planned Phase ... proposed for NDA filing, manufacturing plans for both drug substance ...
Cached Biology Technology:Cellectis Announces a Ten-Fold Increase in Nuclease Production Capacity in 2011 2CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics 2CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics 3CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics 4Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad 2Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad 3Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad 4Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad 5
(Date:7/24/2014)... two factors that characterize sustainable university and college ... qualified physics teachers. Specifically, one or more faculty ... in combination with institutional motivation and commitment can ... Engineering and Math (STEM) teacher shortages are especially ... way for institutions seeking to increase the number ...
(Date:7/24/2014)... MADISON A multi-institutional team of researchers has developed ... tract. This safe, noninvasive method for assessing the function ... could lead to better diagnosis and treatment of gut ... bacterial overgrowth, irritable bowel syndrome and inflammatory bowel disease ... serious side effects in patients with diseases such as ...
(Date:7/24/2014)... biodiversity and one of the most species richness biome ... However, current levels of diversity might be still underestimated. ... in the description of new endemic species of this ... availability of samples for DNA analysis. , Using ... morphological analysis, researchers from the University of Richmond ...
Breaking Biology News(10 mins):Creating sustainable STEM teacher preparation programs 2New imaging agent provides better picture of the gut 2A tiny new species of frog from Brazil with a heroic name 2
... 10 years has seen a huge increase in the popularity ... kept in our homes are monkeys, tarantulas, iguanas, salamanders, snakes, ... around the world develop their conservation and captive breeding programmes ... of exotic animals. To help develop that ...
... have argued that environmental regulations can negatively impact ... by George Mason University researcher Nicole Darnall shows ... not only offset the costs of regulations, but ... which looked at more than 2,600 manufacturing facilities ...
... give birth to offspring who become even heavier, resulting ... of Medicine researchers in Houston who found that chemical ... phenomenon called epigenetics -- could affect successive generations of ... United States and it,s increasingly recognized as a worldwide ...
Cached Biology News:The exotic side of veterinary science 2The exotic side of veterinary science 3Corporations can profit from being environmentally friendly 2The epigenetics of increasing weight through the generations 2
... DNA Engine Dyad instrument is the most ... Featuring MJ's world-class thermal performance, the Dyad ... as well as point-and-click navigation via touch ... can be easily and economically expanded to ...
...
Practical tool for easy, effective sealing of 0.2ml PCR tubes and plates using cap strips....
... RT Telomerase Detection Kit is ... assay for the fluorometric detection ... telomerase activity. It incorporates refinements ... and adds the ability to ...
Biology Products: